# Grupo Sabin

> Grupo Sabin is a privately held Brazilian health group built around clinical laboratories, diagnostic imaging, vaccination and genomics. Founded in Brasília in 1984 by Janete Vaz and Sandra Soares Costa, it reported 362 units, approximately seven million annual customers and R$1.9 billion in gross operating revenue for 2025. Amparo Saúde adds primary care and population health management; Rita Saúde connects patients with affordable services.

- **Founded:** 1984
- **Headquarters:** Brasília, Brazil
- **Founders:** Janete Ribeiro Vaz (Cofounder; chair of the board), Sandra Soares Costa (Cofounder; vice-chair of the board)
- **Products:** Sabin Diagnóstico e Saúde, Sabin Genômica, Amparo Saúde, Rita Saúde, Skyhub.bio
- **Notable:** 2025 reported footprint: 362 units in 78 cities and all five Brazilian regions., R$1.9 billion reported 2025 gross operating revenue., Completed the NTO 4.0 laboratory modernization in 2025.

## Products & services

- **Sabin Diagnóstico e Saúde** — Clinical analysis, anatomical pathology, diagnostic imaging, immunization, executive check-ups and, from 2025 in Brasília, drug infusion services.
- **Sabin Genômica** — Clinical genetic testing and specialized molecular diagnostics; 2025 launches included a DPYD gene test and a PCR-based acute myeloid leukemia subtype test.
- **Amparo Saúde** — Primary care and population health management for employers, insurers and eligible beneficiaries, using dedicated teams, telemedicine and in-person clinics.
- **Rita Saúde** — Launched in March 2021; a digital service connecting patients to consultations, tests and pharmacy discounts. Its public site lists Rita + Saúde at R$49.90 monthly; terms and prices can change.
- **Skyhub.bio** — Open innovation hub launched in 2020 to connect health startups with technical expertise and opportunities to validate solutions.

## Achievements

- 2025 reported footprint: 362 units in 78 cities and all five Brazilian regions.
- R$1.9 billion reported 2025 gross operating revenue.
- Completed the NTO 4.0 laboratory modernization in 2025.
- College of American Pathologists accreditation milestone in 2019.
- Named among the five most innovative medical-services companies in Valor Inovação Brasil 2025, according to its innovation page.
- Instituto Sabin reported cumulative social investment above R$72 million and more than 3.4 million people benefited over two decades.

## Latest updates

- **2025-03** — R$90 million central laboratory technology project with Roche publicly detailed by Medicina S/A.
- **2025-12** — The 2025 report records 17 new group units during the year, completion of NTO 4.0 and R$1.9 billion in gross operating revenue.
- **2025-12** — New services during 2025 included drug infusion in Brasília and a digital unit using online appointments and self-service check-in.

## Links

- Website: https://gruposabin.com.br
- LinkedIn: https://www.linkedin.com/company/grupo-sabin/
- YouTube: https://www.youtube.com/@sabinbr_
- Instagram: https://www.instagram.com/sabinbr_/
- Facebook: https://www.facebook.com/sabindiagnosticoesaude

---

Profile page: https://yespress.io/grupo-sabin
Published by YesPress — https://yespress.io
Last updated: 2026-10-10